natgillin/translations-raw huggingface dataset:
the zofenopril calcium comprises less than 0.1% of zofenopril calcium in other polymorphic or amorphous forms; and/or 
zofenopril kalcij sadrži manje od 0.1% zofenopril kalcija u drugim polimorfnim ili amorfnim oblicima; i/ili
the zofenopril calcium comprises less than 3% of chemical impurities other than zofenopril calcium in other polymorphic or amorphous forms. 
zofenopril kalcij sadrži manje od 3% kemijskih nečistoća različitih od zofenopril kalcija u drugim polimorfnim ili amorfnim oblicima.
use as a medicament; and/or 
uporabu kao lijek; i/ili
reducing blood pressure; and/or 
snižavanje krvnog tlaka; i/ili
treating or preventing hypertension, cardiac decompensation, myocardial infarction, acute myocardial infarction, heart failure or chronic heart failure. 
liječenje ili prevencija hipertenzije, srčane dekompenzacije, infarkta miokarda, akutnog infarkta miokarda, zatajenja srca ili kroničnog zatajenja srca.
the hydrated zofenopril calcium is dried under an inert atmosphere; and/or 
hidrirani zofenopril kalcij se suši u inertnoj atmosferi; i/ili
the hydrated zofenopril calcium is dried under an inert nitrogen flow atmosphere; and/or 
hidrirani zofenopril kalcij se suši u inertnoj atmosferi strujanja dušika; i/ili
the hydrated zofenopril calcium is dried under an inert nitrogen flow atmosphere with a flow rate of about 500 ml/min; and/or 
hidrirani zofenopril kalcij se suši u inertnoj atmosferi strujanja dušika s udjelom protoka od otprilike 500 mL/min; i/ili
the hydrated zofenopril calcium is dried until the moisture content is less than about 0.5%; and/or (viii) the hydrated zofenopril calcium is dried for approximately 120 minutes or less; and/or 
hidrirani zofenopril kalcij se suši do sadržaja vlage manjeg od otprilike 0.5%; i/ili (viii) hidrirani zofenopril kalcij se suši tijekom približno 120 minuta ili manje; i/ili
the hydrated zofenopril calcium is dried for approximately 60 minutes or less; and/or 
hidrirani zofenopril kalcij se suši tijekom približno 60 minuta ili manje; i/ili
the hydrated zofenopril calcium is dried for approximately 30 minutes or less. 
hidrirani zofenopril kalcij se suši tijekom približno 30 minuta ili manje.
A pharmaceutical composition according to claim 7: 
Farmaceutski sastav u skladu s patentnim zahtjevom 7:
wherein the composition is for oral or parenteral administration; and/or 
pri čemu je sastav za oralnu ili parenteralnu primjenu; i/ili
wherein the composition is in the form of a tablet, capsule, syrup, suspension or elixir for oral administration or in a form suitable for preparing a syrup, suspension or elixir for oral administration, or wherein the composition is in the form of a sterile solution or suspension for parenteral administration or in a form suitable for preparing a sterile solution or suspension for parenteral administration; and/or 
pri čemu je sastav u obliku tablete, kapsule, sirupa, suspenzije ili eliksira za oralnu primjenu ili u obliku pogodnom za pripremu sirupa, suspenzije ili eliksira za oralnu primjenu, ili pri čemu je sastav u obliku sterilne otopine ili suspenzije za parenteralnu primjenu ili u obliku pogodnom za pripravu sterilne otopine ili suspenzije za parenteralnu primjenu; i/ili
wherein the composition is in unit dosage form comprising zofenopril calcium crystalline form D in an amount of from 1mg to 500mg; and/or 
pri čemu je sastav u obliku jediničnog doziranja koji sadrži zofenopril kalcij kristaliničnog oblika D u količini od 1 mg do 500 mg; i/ili
for reducing blood pressure; and/or 
za snižavanje krvnog tlaka; i/ili
for treating or preventing hypertension, cardiac decompensation, myocardial infarction, acute myocardial infarction, heart failure or chronic heart failure. 
za liječenje ili prevenciju hipertenzije, srčane dekompenzacije, infarkta miokarda, akutnog infarkta miokarda, zatajenja srca ili kroničnog zatajenja srca.
Use of zofenopril calcium crystalline form D according to any one of claims 1 to 4, or use of zofenopril calcium crystalline form D prepared by a process according to claim 5 or 6, or use of a composition according to claim 7 or 8, for the manufacture of a medicament for treating or preventing hypertension, cardiac decompensation, myocardial infarction, acute myocardial infarction, heart failure or chronic heart failure. 
Uporaba zofenopril kalcija kristaliničnog oblika D u skladu s bilo kojim od patentnih zahtjeva 1 do 4, ili uporaba zofenopril kalcija kristaliničnog oblika D pripravljenog postupkom u skladu s patentnim zahtjevom 5 ili 6, ili uporaba sastava u skladu s patentnim zahtjevom 7 ili 8, za proizvodnju lijeka za liječenje ili prevenciju hipertenzije, srčane dekompenzacije, infarkta miokarda, akutnog infarkta miokarda, zatajenja srca ili kroničnog zatajenja srca.
A use according to claim 9 or 10, wherein the amount of zofenopril calcium crystalline form D to be administered is from 0.1mg to 100mg per kg per day. 
Uporaba u skladu s patentnim zahtjevom 9 ili 10, pri čemu količina zofenopril kalcija kristaliničnog oblika D za primjenu iznosi 0.1 mg do 100 mg po kg po danu.
A compound according to claim 3, wherein A1 is absent or is selected from the group consisting of methylene, ethylene, propylene, butylene, pentylene, hexylene, heptylene, octylene and nonylene, A2 is absent or is selected from the group consisting of methylene and oxadiazolene, B is selected from the group consisting of phenylene and cyclohexylene or is absent, C is absent, D is absent or is selected from methylene, ethylene, propylene, butylene, pentylene, hexylene, heptylene, octylene, nonylene, phenylene and oxadiazolene; G is selected from the group consisting of fluoro-biphenylene and phenylene. 
Spoj prema patentnom zahtjevu 3, naznačen time da je A1 odsutan ili je odabran iz sljedeće skupine: metilen, etilen, propilen, butilen, pentilen, heksilen, heptilen, oktilen te nonilen, A2 je odsutan ili je odabran iz sljedeće skupine: metilen i oksadiazolen, B je odabran iz sljedeće skupine: fenilen i cikloheksilen ili je odsutan, C je odsutan, D je odsutan ili je odabran od sljedećih: metilen, etilen, propilen, butilen, pentilen, heksilen, heptilen, oktilen, nonilen, fenilen te oksadiazolen, G je odabran iz sljedeće skupine: fluorbifenilen i fenilen.
A compound according to claim 6, wherein A1 is absent or is selected from the group consisting of methylene, ethylene, propylene, butylene, pentylene, hexylene, heptylene, octylene and nonylene, A2 is absent, B is absent, C is absent, D is absent or is selected from methylene, ethylene, propylene, butylene, pentylene, hexylene, heptylene, octylene and nonylene; G is phenylene. 
Spoj prema patentnom zahtjevu 6, naznačen time da je A1 odsutan ili je odabran iz sljedeće skupine: metilen, etilen, propilen, butilen, pentilen, heksilen, heptilen, oktilen te nonilen, A2 je odsutan, B je odsutan, C je odsutan, D je odsutan ili je odabran od sljedećih: metilen, etilen, propilen, butilen, pentilen, heksilen, heptilen, oktilen te nonilen; G je fenilen.
A compound according to claim 1, wherein Q is a group of formula Q1, Q2, Q3, Q4, Q5 or Q6, Z is H or OH; Y1 is a group of formula -A1-C-B-D-(CH2)n-E- Y1 wherein A1 is selected from the group consisting of methylene, ethylene, propylene, butylene, pentylene and hexylene; C is absent or is selected from the group consisting of -O-, -CO-, -OC(O)-, C11, C 13, C 14, C16, C 17, C18 wherein R7 is H or is selected from the group consisting of methyl, ethyl and isopropyl and C 15 wherein n is 0 or 1 and R8 is ethoxycarbonyl; B is absent or is selected from phenylene, piperidinylene, cyclopropylene, cyclohexylene, piridinediyl, furanediyl, oxazolediyl, optionally substituted by one or more halogens; D is absent or is selected from methylene, -C(CH3)2-, phenylene and oxadiazolylene; n is 0 or an integer from 1 to 2; E is -O-; G is selected from phenylene and biphenylene, optionally substituted by one or more substituents selected from the group consisting of fluorine, phenyl and 2-thiophenyl. 
Spoj prema patentnom zahtjevu 1, naznačen time da Q jest skupina formule Q1, Q2, Q3, Q4, Q5 ili Q6, Z je H ili OH, Y1 je skupina formule [image] gdje je A1 odabran iz sljedeće skupine: metilen, etilen, propilen, butilen, pentilen te heksilen, C je odsutan ili je odabran iz sljedeće skupine -O-, -CO-, -OC(O)-, C11, C13, C14, C16, C17, C18, gdje R7 jest H ili je odabran iz sljedeće skupine: metil, etil, izopropil te C15 gdje n jest 0 ili 1, a R8 je etoksikarbonil, B je odsutan ili je odabran od sljedećih: fenilen, piperidinilen, ciklopropilen, cikloheksilen, piridindiil, furandiil, oksazoldiil, koji može biti supstituiran s jednim ili više halogena, D je odsutan ili je odabran od sljedećih: metilen, -C(CH3)2-, fenilen i oksadiazolilen, n je 0 ili je cijeli broj od 1 do 2, E je -O-, G je odabran od sljedećih: fenilen i bifenilen, koji može biti supstituiran s jednim ili više supstituenata odabranih od sljedećih: fluor, fenil i 2-tiofenil.
Use of a compound of formula I according to any one of claims 1-13 for the manufacture of a medicament for the prevention and/or treatment of broncho-obstructive or inflammatory diseases, preferably asthma or chronic bronchitis or chronic obstructive pulmonary disease (COPD). 
Upotreba spoja formule I prema bilo kojem od patentnih zahtjeva 1-13, naznačena time da je za pripravu lijeka za sprječavanje i/ili liječenje bronho-obstuktivnih ili uplanih bolesti, preferirano astne ili kroničnog bronhitisa ili obstruktivne plućne bolesti (COPD).
mixing a compound of formula (III), with 0.5 to 0.8 equivalents of an enantiomerically pure protected amino acid selected from L-Boc-phenylalanine or L-Boc-leucine to form a diastereoisomeric salt; 
miješanje spoja s formulom (III), [image] do 0.8 ekvivalenata enantiomerno čiste zaštićene amino kiseline odabrane od L-Boc-fenilalanina ili L-Boc-leucina da se dobije diastereoizomerna sol;
crystallizing said salt to deliver a protected amino acid salt of a compound of formula (IV), 
kristalizaciju navedene soli da nastane zaštićena sol amino kiseline spoja s formulom (IV), [image]
reacting the product from c) with benzyl chloroformate in the presence of a suitable base, such as potassium carbonate. 
reakciju produkta iz koraka c) s benzil kloroformatom u prisutnosti prikladne baze, kao što je kalijev karbonat.
The dosage form according to claim 6, characterized in that it is suitable for oral, intravenous, intraarterial, intraperitoneal, intradermal, transdermal, intrathekal, intramuscular, intranasal, transmucosal, subcutaneous, or rectal administration. 
Oblik doziranja prema zahtjevu 6, naznačen time da je prikladan za oralno, intravenozno, intraarterijalno, intraperitonealno, intradermalno, transdermalno, intramuskularno, intratekalno, intranazalno, transmukozno, potkožno, ili rektalno davanje.
The combination according to claim 9, wherein the pain is inflammatory pain. 
Kombinacija prema zahtjevu 9, naznačena time da bol je upalna bol.
Use of the combination according to any one of claims 9 to 11 for the manufacture of a medicament for the treatment of pain in a mammal, which comprises administering an effective amount of the combination according to any one of claims 1 to 4 to the mammal. 
Uporaba kombinacije prema bilo kojem od zahtjeva 9 do 11 naznačena time da je za proizvodnju lijeka za liječenje boli kod sisavca, koje se sastoji od davanja sisavcu učinkovite količine kombinacije prema bilo kojem od zahtjeva 1 do 4.
A process for preparing the crystalline freebase of Claim 1, comprising contacting biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]-methylamino}ethyl)piperidin-4-yl ester with a solvent consisting of acetonitrile, the ratio of milligrams of the ester to total milliliters of acetonitrile being 100:1, and the acetonitrile being added in two steps. 
Postupak za pripremu kristalne slobodne baze u skladu s patentnim zahtjevom 1, naznačen time, da uključuje dovođenje u kontakt bifenil-2-ilkarbaminska kiselina 1-(2-{[4-(4-karbamoilpiperidin-1-ilmetil)benzoil]-metilamino}etil)piperidin-4-il estera s otapalom koje se sastoji od acetonitrila, pri čemu omjer miligrama estera u odnosu na ukupni broj mililitara acetonitrila iznosi 100:1, a acetonitril se dodaje u dva koraka.
A fixed dose combination comprising benazepril hydrochloride and pimobendan in a ratio of 2: 1, in form of a bilayer tablet, wherein the benazepril layer comprises 2.5, 5 or 10 mg benazepril hydrochloride which are contained in the form of pellets, and wherein the pimobendan layer comprises 1.25, 2.5 or 5 mg pimobendan. 
Kombinacija s fiksnom dozom, naznačena time što sadrži benazepril-hidroklorid i pimobendan u omjeru od 2:1, u obliku dvoslojne tablete, gdje sloj s benazeprilom sadrži 2,5, 5 ili 10 mg benazepril-hidroklorida, sadržanog u obliku peleta, te gdje sloj s pimobendanom sadrži 1,25, 2,5 ili 5 mg pimobendana.
A fixed dose combination of claim 1 wherein the pellets of the benazepril layer comprise 5% benazepril by weight of the layer. 
Kombinacija s fiksnom dozom u skladu s patentnim zahtjevom 1, naznačena time što pelete u sloju s benazeprilom sadrže 5% benazeprila, težinski, po sloju.
A fixed dose combination of claim 4 wherein the excipients of the benazepril layer have a particle size of from 200 to 400 µm. 
Kombinacija s fiksnom dozom u skladu s patentnim zahtjevom 4, naznačena time što pomoćne tvari u sloju s benazeprilom imaju veličinu čestica od 200 do 400 µm.
A fixed dose combination of claim 10 which is administered twice daily. 
Kombinacija s fiksnom dozom u skladu s patentnim zahtjevom 10, naznačena time što se primjenjuje dva puta dnevno.
the benazepril pellets obtained in b) are further mixed with excipients to obtain a blend, and 
pelete s benazeprilom dobivene u b) dodatno se pomiješaju s pomoćnim tvarima kako bi se dobila smjesa, te
the granulate and the blend obtained in a) and c) are compressed together to obtain a bilayer tablet. 
granulat i smjesa dobivene u a) i c) se komprimiraju zajedno kako bi se dobila dvoslojna tableta.
The DMF and glatiramer acetate for use according to any one of claims 1 to 4, wherein the DMF and the glatiramer acetate are formulated into separate dosage forms for administration separately or together. 
Kombinacijska terapija namijenjena upotrebi u skladu s bilo kojim od patentnim zahtjevima 1 do 4, naznačena time što su DMF i/ili MMF i glatiramer-acetat formulirani u odvojene oblike doziranja namijenjene primjeni odvojeno ili zajedno.
The DMF and interferon-beta for use according to claim 16, wherein the DMF is to be administered to the subject two times per day (BID) equivalent to a total daily dose of 480 mg per day. 
Kombinacijska terapija namijenjena upotrebi u skladu s patentnim zahtjevom 14, naznačena time što DMF na subjektu treba primijeniti dva puta dnevno (BID), što je ekvivalent ukupnoj dnevnoj dozi od 480 mg dnevno.
A pharmaceutical composition comprising the isolated antibody or fragment of any one of the preceding claims and a pharmaceutically acceptable carrier. 
Farmaceutska kompozicija koja sadrži izolirano antitijelo ili fragment iz bilo kojeg od patentnih zahtjeva 1-7 i farmaceutski prihvatljiv nosač.
inflammatory bowel disease; 
ii) upalna bolest crijeva;
systemic inflammatory condition, wherein optionally the systemic inflammatory condition is cytokine storm or hypercytokinemia, systemic inflammatory response syndrome (SIRS), graft versus host disease (GVHD), acute respiratory distress syndrome (ARDS), severe acute respiratory distress syndrome (SARS), catastrophic anti-phospholipid syndrome, severe viral infections, influenza, pneumonia, shock, or sepsis; rheumatoid arthritis; or 
iv) sistemsko upalno stanje, pri čemu je sistemsko upalno stanje opcionalno: citokinska oluja ili hipercitokinemija, sindrom sistemskog upalnog odgovora (SIRS), graft versus host sindrom (GVHD), akutni respiratorni distres sindrom (ARDS), teški akutni respiratorni distres sindrom (SARS), katastrofalni anti-fosfolipidni sindrom, teške virusne zaraze, gripa, upala pluća, stanje šoka ili sepsa;
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an isolated antibody or antigen-binding fragment thereof that binds to a free C5a polypeptide, wherein the free C5a is a human polypeptide (hC5a) having the amino acid sequence depicted in SEQ ID NO:1, and wherein the antibody or antigen-binding fragment thereof binds to the free hC5a polypeptide in vitro with a KD that is less than 1.25 x 10-9 M as measured by surface plasmon resonance (SPR) in the presence of a molar excess of uncleaved, native human C5; 
Izolirano protutijelo ili njegov fragment koji veže antigen koje se veže na slobodni C5a polipeptid, pri čemu slobodni C5a je ljudski polipeptid (hC5a) koji ima sekvencu aminokiseline prikazanu u SEQ ID NO:1, te pri čemu se protutijelo ili njegov fragment koji veže antigen veže na slobodni hC5a polipeptid in vitro sa KD koji je manji od 1.25 x 10-9 M kako je izmjereno površinskom plazmonskom rezonancijom (SPR) u prisutnosti molarnog suviška ne rascijepljenog, izvornog ljudskog C5, te je naznačeno time da protutijelo ili njegov fragment koji veže antigen sadrži:
A system for preparing a beverage, the system comprising: 
Sustav za pripremu napitka koji obuhvaća sljedeće:
A compound for use according to Claim 12, wherein at least one other therapeutic agent is imiglucerase or 1,5-(butylimino)-1,5-dideoxy-D-glucitol. 
Spoj za uporabu prema zahtjevu11, naznačen time da najmanje jedno drugo terapijsko sredstvo je imigluceraza ili 1,5-(butilimino)-1,5-dideoksi-D-glucitol.
The pharmaceutical composition of claim 1, wherein said compound is a modulator for use in the treatment of cystic fibrosis, wherein it has effect on CFTR-dependent ion transport across cellular membrane and/or it has the ability to increase the number of mutant CFTR proteins that reach the cell surface. 
Modulator formule (I) u skladu s patentnim zahtjevom 1, za uporabu u liječenju cistične fibroze pri čemu on ima učinak na CFTR-ovisan transport iona kroz staničnu membranu i/ili ima sposobnost povećanja broja mutiranih CFTR proteina koji dosežu površinu stanice.
The pharmaceutical composition of claim 1, wherein said compound is a modulator for use in the treatment of cystic fibrosis, wherein it has a stabilizing effect on the structure of the mutant CFTR protein and/or blocks the interaction with cellular proteins responsible for the premature degradation of mutant CFTR. 
Modulator formule (I) u skladu s patentnim zahtjevom 1, za uporabu u liječenju cistične fibroze pri čemu on ima stabilizirajući učinak na strukturu mutiranog CFTR proteina i/ili blokira međudjelovanje sa staničnim proteinima odgovornim za preuranjenu razgradnju mutiranog CFTR.
Structure according to any one of claims 6 to 8, characterized in that said stand members (38) include a support member (40a, 40b, 40c) and at least a foot member (44), in which said support and foot members (40a, 40b, 40c, 44) have generally flat configurations and can be mutually connected according to a perpendicular configuration. 
Konstrukcija prema bilo kojem od zahtjeva 6 do 8, naznačena time, da navedeni podupirači (38) uključuju nosivi element (40a, 40b, 40c) i barem jedno stopalo (44), gdje spomenuti nosivi elementi i stopala (40a, 40b, 40c, 44) imaju općenito plosnate konfiguracije i mogu biti zajedno spojeni u skladu s okomitom konfiguracijom.
Structure according to claim 18, characterized in that it comprises holes formed in the containers (12c) of said platforms (10), in which holes pipes are inserted to which a refrigeration or heating fluid is fed in order to directly heat or cool the earth contained in said containers (12c). 
Konstrukcija prema zahtjevu 18, naznačena time, da ona obuhvaća rupe ostvarene u posudama (12c) od navedenih platformi (10), dok su u tim rupama umetnute cijevi koje se pune fluidom za hlađenje ili grijanje, kako bi se izravno grijala ili hladila zemlja u spomenutim posudama (12c).
treating the reaction product obtained in step (a) with benzene sulfonic acid in an organic solvent or an organic solvent mixture, such as to produce the compound (P), and optionally (c) isolating the compound (P) by methods routinely used in synthetic organic chemistry. 
tretiranje reakcijskog produkta dobivenog u koraku (a) benzen sulfonskom kiselinom u organskom otapalu ili smjesi organskih otapala, kako bi se proizveo spoj (P), i po izboru izoliranje spoja (P) metodama rutinski korištenim u sintetskoj organskoj kemiji.
the compound of formula (B) 
spoja formule (B) [image] .
A capsule according to claim 1, wherein the cup further comprises a flange-like rim (104) extending outwardly of the circumferential wall (102) at the second end, wherein the at least one projection (127) is provided on the flange-like rim (104). 
Kapsula prema patentnom zahtjevu 1, pri čemu čašica još sadrži obod (104) u obliku prirubnice koji se pruža prema van od obodnog zida (102) na drugom kraju, pri čemu je najmanje jedan ispupčeni dio (127) predviđen na obodu (104) u obliku prirubnice.
A capsule according to any one of claims 1-2, wherein the at least one projection (107) is circumferential with respect to the capsule (110). 
Kapsula prema jednom od patentnih zahtjeva 1-2, pri čemu najmanje jedan ispupčeni dio (127) je raspoređen po obodu u odnosu na kapsulu (119).
A capsule according to any one of claims 1-3, wherein the at least one projection (127) is provided on separate regions along a periphery of the capsule (110). 
Kapsula prema jednom od patentnih zahtjeva 1-3, pri čemu najmanje jedan ispupčeni dio (127) postoji na odvojenim područjima duž periferije kapsule (110).
A capsule according to any one of the preceding claims, wherein the projection (127) is made of the same material as the cup. 
Kapsula prema jednom od prethodnih patentnih zahtjeva, pri čemu je ispupčeni dio (127) napravljen od istog materijala kao čašica.
A capsule according to any one of the preceding claims, wherein the lid (14) is connected to cup at the second end of the circumferential wall (102), e.g. 
Kapsula prema jednom od prethodnih patentnih zahtjeva, pri čemu je poklopac (14) povezan na čašicu na drugom kraju obodnog zida (102), npr.
A capsule according to claim 37, wherein the capsule (2; 110) is hermetically closed. 
Kapsula prema patentnom zahtjevu 14, pri čemu je kapsula (110) hermetički zatvorena.
A capsule according to claim 37, wherein the lid (14) and/or bottom (18) is porous and/or comprises openings for allowing a liquid to enter and/or exit the inner space. 
Kapsula prema patentnom zahtjevu 14, pri čemu je poklopac (14) i/ili dno (18) porozno i/ili sadrži otvore da tekućini omogući ulaz i/ili izlaz u unutrašnji prostor.
A capsule according to any one of the preceding claims, wherein the capsule (2; 110) is disposable. 
Kapsula prema jednom od prethodnih patentnih zahtjeva, pri čemu je kapsula (110) za jednokratnu upotrebu.
A system according to claim 41, wherein the receptacle (6; 108) is provided in a form of an enclosing member. 
Sistem prema patentnom zahtjevu 18, pri čemu je posuda (108) izvedena u obliku obuhvatnog elementa (108).
A system according to claim 19 comprising a capsule according to claim 12, wherein the further ridge (40) is arranged to abut against an outer circumferential surface of the enclosing member (108). 
Sistem prema patentnom zahtjevu 19 obuhvaća kapsulu (110) prema patentnom zahtjevu 11, pri čemu je još jedan ispust (40) raspoređen da se nasloni na vanjsku obodnu površinu obuhvatnog elementa (108).
providing a beverage brewing device comprising a receptacle (6; 108) for interacting with the capsule (2; 110); 
dobivanja uređaja (4) za kuhanje pića koji sadrži posudu (108) za uzajamno djelovanje sa kapsulom (110);